AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter when the medical device maker's revenues increased by
ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9%
Categories
pharmaceuticals
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic
Earnings: Trxade Health (MEDS) reports 16% rise in FY22 revenue; loss narrows
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a double-digit increase in revenues for fiscal 2022. The company's
Walgreens Boots Alliance (WBA) shifts to expansion mode. Will it pay off?
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a market leader in retail pharmacy, has regularly revised its business model to better align with
Ocean Biomedical presents novel malaria therapeutic discoveries at NIH Laboratory of Malaria Vaccinology and Immunology
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Fundamental Research Corp. initiates coverage of Ocean Biomedical (OCEA) with “Buy” recommendation
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday said that Fundamental Research Corp. initiated equity analyst coverage of its stock with a “Buy”
ANI Pharmaceuticals Inc (ANIP) Q4 2022 Earnings Call Transcript
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Q4 2022 Earnings Call dated Mar. 09, 2023. Corporate Participants: Judy DiClemente -- Investor Relations Nikhil Lalwani -- President and Chief Executive
Ocean Biomedical provides positive research data on anti-tumor pathway; stock climbs
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) released details of discoveries that have potential applications for tumor suppression across multiple cancer pathways.
Jazz Pharmaceuticals PLC (JAZZ) Q4 2022 Earnings Call Transcript
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q4 2022 Earnings Call dated Mar. 01, 2023. Corporate Participants: Darren Fox -- Executive Director, Investor Relations Bruce C. Cozadd -- Chairman
Agilent (A) Q1 2023 earnings rise on higher revenues
Agilent Technologies (NYSE: A) has announced first-quarter 2023 financial results, reporting an increase in adjusted profit and revenues. The Santa Clara, California-based
Ocean Biomedical co-founder Jake Kurtis gets new patent for novel malaria vaccine target
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jonathan Kurtis received a new patent for his discovery related
BioMarin Pharmaceutical Inc (BMRN) Q4 2022 Earnings Call Transcript
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q4 2022 Earnings Call dated Feb. 27, 2023. Corporate Participants: Traci McCarty -- Group Vice President of Investor Relations Jean-Jacques
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
The global pharmaceutical market is expected to cross $1.5 trillion this year, which represents a 4-5% annual growth over the past five
Zoetis Inc (ZTS) Q4 2022 Earnings Call Transcript
Zoetis Inc (NYSE: ZTS) Q4 2022 earnings call dated Feb. 14, 2023 Corporate Participants: Steve Frank -- Vice President, Investor Relations Kristin Peck -- Chief Executive
Vertex Pharmaceuticals (VRTX) Earnings: 4Q22 Key Numbers
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported total revenues of $2.3 billion for the fourth quarter of 2022. This compares to $2 billion in
Regeneron Pharmaceuticals Inc (REGN) Q4 2022 Earnings Call Transcript
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2022 earnings call dated Feb. 03, 2023 Corporate Participants: Ryan Crowe -- Vice President, Investor Relations Leonard S.
CI Earnings: Highlights of Cigna Corp.’s Q4 2022 results
Cigna Corporation (NYSE: CI) has reported an increase in net income for the fourth quarter of 2022 when the healthcare services provider's
Infographic: Highlights of Gilead Sciences (GILD) Q4 2022 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when
Earnings: Regeneron Pharmaceuticals (REGN) Q4 profit falls as revenues drop 31%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Friday reported a sharp fall in fourth-quarter revenues and adjusted earnings. Total revenues plunged 31% year-over-year
Eli Lilly and Company (LLY) Q4 2022 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q4 2022 earnings call dated Feb. 02, 2023 Corporate Participants: Joe Fletcher -- Senior Vice President of Investor
Eli Lilly and Company (LLY) Earnings: 4Q22 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported fourth quarter 2022 earnings results today. Revenue fell 9% year-over-year to $7.3 billion. Reported net income